First patients receive experimental immune cell therapy for Tough-to-Treat lung cancer
NCT ID NCT03392064
Summary
This is a very early, first-in-human study to check the safety and side effects of an experimental treatment called AMG 119 in adults with small cell lung cancer that has come back or stopped responding to standard chemotherapy. AMG 119 is a type of CAR T-cell therapy, where a patient's own immune cells are modified in a lab to target a protein found on this cancer. The main goal is to find a safe dose, while also looking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Tampa, Florida, 33612, United States
-
Research Site
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.